Development of New Cancer Treatment by Identifying and Targeting Pathogenic Abnormalities of Genes

Dear Colleagues,

A number of diseases still require the development of new drugs or the improvement of therapeutic efficacy of current drugs. In order to meet the clinical needs, a number of studies have so far been devoted to clarifying previously unrecognized mechanisms of diseases.

Abnormalities of genes bring about changes in cellular functions, and thereby lead to the development of specific pathologies, in particular cancers. Therefore, the identification of such abnormalities provides a great advantage to the invention of new cancer treatment strategies.

Currently, abnormalities associated with cancers can be approached by small molecule drugs, monoclonal antibodies or gene therapy. However, it has been clarified that tumorigenic abnormalities of genes include not only mutations, but also aberrant alternative splicing, and uncontrolled gene expression by epigenetic factors and non-coding genes, most of which are not sufficiently understood yet.

This Special Issue calls for original articles, short reports, reviews, and perspectives covering novel tumorigenic abnormalities of coding and non-coding genes, and epigenetic factors that advance our current understanding of cancers. Besides, studies investigating novel small molecules, antibodies, and gene therapy targeting tumorigenic abnormalities are also welcome.

We look forward to your contributions.

Dr. Hiroyuki Tsuchiya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.